Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MP0250||MP-0250||MP0250 is a protein therapeutic that targets VEGFA, HGF, and human serum albumin, resulting in decreased downstream signaling and reduced angiogenesis, and potentially leading to decreased tumor growth (PMID: 29568363, PMID: 29228696).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03418532||Phase Ib/II||MP0250||MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC||Terminated||USA||0|